Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study

British Journal of Rheumatology

Volumn 35, Issue 7, 1996, Pages 669-675

  Manger, Karin ^a,b   Kalden, J R ^a   Manger, B ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cyclosporin A; Proteinuria; Systemic lupus erythematosus; Therapy

Indexed keywords

CYCLOSPORIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; MALE; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0030004197     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.7.669     Document Type: Article

References (40)

1. Kahan BD. Cyclosporine. N Engl J Med 1989;321: 1725-34.
2. Feutren G. Cyclosporine A: recent developments in the mechanisms of action and clinical application. Curr Opin Immunol 1989;2:39-245.
3. Bloemena E, van Oers MHJ, Weinreich S, Yong SL, Schellekens PTA. Prednisolone and cyclosporin exert differential inhibitory effects on T-cell proliferation in vitro. Clin Immunol Immunopathol 1988;48:380-91.
4. Mayus JL, Semper KF, Pisetsky DS. Inhibition of in vitro anti-DNA B-cell responses by cyclosporine. Cell Immunol 1985;94:195-204.
5. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus: Arthritis Rheum 1982;25:1271-7.
6. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. 11. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
7. Handwerger BS. Lymphocyte biology in lupus. Curr Opin Rheumatol 1990;2:749-61.
8. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Exp Med 1985;161: 378-91.
9. Israel-Biet D, Noel LH, Back MA, Dardenne M, Bach JF. Marked reduction of DNA antibody production and glomerulonephritis in thymulin (FTS-Zn) or cyclosporin A treated (NZB × NZW) Fl mice. Clin Exp Immunol 1983;54:359-65.
10. Jones MG, Harris G. Prolongation of life in female (NZB × NZW) hybrid F1 mice by cyclosporin A. Clin Exp Immunol 1985;59:1-9.
11. Gunn HC. Sucessful treatment of autoimmunity in (NZB × NZW) F1 mice with cyclosporin and (Nva2)- cyclosporin. Reduction of autoantibodies. Clin Exp Immunol 1986;64:225-33.
12. Isenberg DA, Snaith ML, Al-Khader AA .et al. Cyclosporin relieves arthralgia, causes angioedema. N Engl J Med 1980;303:754.
13. Isenberg DA, Snaith ML, Morrow WJ et al. Cyclosporin A for the treatment of systemic lupus eiythematosus. Int J Immunopharmacol 1981;3:163-9.
14. Halloran PF, Cole EH, Bookman AA, Urowitz MB, Clarke WTW. Possible beneficial effect of ciclpsporin in some cases of severe systemic lupus erythematosus. In: Schindler R, ed. Cyclosporin in autoimmune diseases. Berlin: Springer, 1985:356-60.
15. Feutren G, Querin S, Tron F et al. The effects of cyclosporine in patients with systemic lupus. Transplant Proc 1986;18:634-44.
16. Deteix P, Lefrancois N, Lavile M, Colon S, Zech P, Traeger J. Open therapeutic trial of ciclosporin in systemic lupus erythematosus. Preliminary results in 4 patients. In: Schindler R, ed. Cyclosporin in autoimmune diseases. Berlin: Springer, 1985:361-5.
17. Miescher PA, Miescher A. Combined ciclosporin-steroid treatment of systemic lupus erythematosus. In: Schindler R, ed. Cyclosporin in autoimmune diseases. Berlin: Springer, 1985:337-45.
18. Miescher PA, Favre H, Chatelanat F, Mihatsch MJ. Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Klin Wochenschr 1987;65:727-36.
19. Feutren G, Querin S, Noel LH et al. Effects of cyclosporin in severe systemic lupus erythematosus. J Pediatr 1987;111:1063-8.
20. Ter Borg EJ, Tegzess AM, Kallenberg COM. Unexpected severe cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Clin Nephrol 1988;29:93-5.
21. Miescher PA, Favre H, Mihatsch MJ. The place of CsA in the treatment of connective tissue diseases. Transplant Proc 1988;20(suppl. 4):224-37.
22. Favre H. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 1989;9(suppl. 1):57-60.
23. Bambauer R, Reinelt B, Pees H et al. Therapeutic plasma exchange and ciclosporin A in severe systemic lupus erythematosus. Transfus Sci 1989;10:147-54.
24. Doria A, Di Lenardo L, Vario S, Calligaro A, Vaccaro E, Gambari PF. Cyclosporin A in a pregnant patient affected with systemic lupus erythematosus. Rheumatol Int 1992;12:77-8.
25. Hussein MM, Mooij JMV, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993;40:160-3.
26. Gerkely P. Cyclosporin therapy of patients with systemic lupus erythematosus. Orv Hetil 1994;135:2591-5.
27. Tokuda M, Kurata N, Mizoguchi A et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus. Arthritis Rheum 1994;37:551-8.
28. Forre O, Bjerkhoel F, Salvesen CF et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987;30:88-92.
29. Bennett WM, Pulliam JP. Cyclosporin nephrotoxicity. Ann Intern Med 1983;99:851-4.
30. Berg KJ, Forre O, Bjerkhoel F et al. Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 1986;29:1180-7.
31. Myers BD, Ross J, Newton L, Leutscher J, Perlroth M. Cyclosporin-associated chronic nephropathy. N Engl J Med 1984;311:699-705.
32. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987;44:135-41.
33. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(suppl. 3):759-71.
34. Feutren G, Mihatsch JM. Risk factors for Cyclosporine- induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
35. Fathman CG, Myers BD. Cyclosporine therapy for autoimune diseases. N Engl J Med 1992;326:1693-5.
36. Drath DB, Kahan BD. Phagocytic cell function in response to immunosuppressive therapy. Arch Surg 1984;119:156-60.
37. Penn I. Cancers following cyclosporine therapy. Transplantation 1987;43:32-5.
38. Olshan AF, Mattison DR, Zwanenburg TSB. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutat Res 1994;317:163-73.
39. Panayi GS, Tugwell P. An international consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993;32(suppl. 1):1-3.
40. Avina-Zubieta JA, Russell AS. Cyclosporin A in the treatment of systemic lupus erythematosus: comment on the article by Tokuda et al. Arthritis Rheum 1994;37: 1711-2.